Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPCG2L)

• Drug Name: Flumazenil Drug Info
• Synonyms: flumazenil; 78755-81-4; Anexate; Flumazepil; Romazicon; Lanexat; Mazicon; Ro 15-1788; Flumazenilum; Flumazenilo; Flumazenilum [Latin]; Flumazenilo [Spanish]; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate; [11C]flumazenil; Ro 151788; Flumazenil (Ro 15-1788); Ro-15-1788; UNII-40P7XK9392; C15H14FN3O3; CHEMBL407; Ro15-1788; BRN 4763661; MLS000028850; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; CHEBI:5103; OFBIFZUFASYYRE-UHFFFAOYSA-N; FlumUP TD; Flumazenil (transdermal patch formulation); Flumazenil (transdermal patch formulation), Coeruleus

Indication

Disease Entry	ICD 11	Status	REF
Benzodiazepine overdose	PC91	Approved	[1]

• Cross-matching ID:
  PubChem CID: 3373
  ChEBI ID: CHEBI:5103
  CAS Number: CAS 78755-81-4
  TTD Drug ID: DMPCG2L
  ACDINA Drug ID: D01087

Molecule-Related Drug Atlas

Drug(s) Targeting GABA(A) receptor alpha-5 (GABRA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[8]
Basmisanil	DMQ8J0U	Alzheimer disease	8A20	Phase 2	[9]
RG-7816	DMD16JK	Autism spectrum disorder	6A02	Phase 1	[10]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[4]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[11]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[12]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[4]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[13]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[4]
CI-218872	DM0RH3S	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting GABA(A) receptor gamma-3 (GABRG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[5]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[9]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[15]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[16]
Thiamylal	DMHDF7B	Anaesthesia	9A78.6	Approved	[15]
Ganaxolone	DMXJMKF	Epileptic seizures	8A61-8A6Z	Approved	[9]
Mebutamate	DM0KYI4	Anxiety disorder	6B00-6B0Z	Approved	[15]
Metharbital	DM5A38V	Epilepsy	8A60-8A68	Approved	[15]
Etomidate	DMZI3WO	Anaesthesia	9A78.6	Approved	[15]
Remimazolam	DMLVSYX	Procedural sedation	JB0C.3	Approved	[17]

Drug(s) Targeting GABA(A) receptor alpha-2 (GABRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[8]
PF-4480682	DMWYJHC	Neuropathic pain	8E43.0	Discontinued in Phase 2	[18]
CGS-17867A	DMMZJY3	Alcohol dependence	6C40.2	Terminated	[19]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[2]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[11]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[12]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[2]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[13]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[2]
CI-218872	DM0RH3S	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting GABA(A) receptor alpha-3 (GABRA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[8]
Adipiplon	DM821BS	Sleep-wake disorder	7A00-7B2Z	Phase 2	[20]
NS-2710	DMMUR6V	Anxiety disorder	6B00-6B0Z	Phase 2	[21]
AZD6280	DMFAZLU	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[22]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[3]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[11]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[12]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[3]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[13]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[3]

Drug(s) Targeting Translocator protein (TSPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[23]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[24]
Oxazepam	DMXNZM4	Alcohol withdrawal delirium		Approved	[25]
Midazolam	DMXOELT	Agitation	6A70.3	Approved	[15]
Temazepam	DM02A65	Insomnia	7A00-7A0Z	Approved	[15]
Alprazolam	DMC7XDN	Anxiety		Approved	[24]
Clotiazepam	DM59AZT	Anxiety disorder	6B00-6B0Z	Approved	[26]
Quazepam	DMY4D87	Insomnia	7A00-7A0Z	Approved	[15]
Eszopiclone	DM8RZ9H	Insomnia	7A00-7A0Z	Approved	[27]
Triazolam	DMETYK5	Insomnia	7A00-7A0Z	Approved	[15]

Drug(s) Affected By Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[29]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[30]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[31]
Methamphetamine	DMPM4SK	Anxiety		Approved	[32]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[33]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[34]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[35]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[36]
Manganese	DMKT129	N. A.	N. A.	Investigative	[37]

Drug(s) Affected By Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[39]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[41]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[29]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[44]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[46]

Drug(s) Affected By Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[47]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[48]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[49]
Naltrexone	DMUL45H	Alcohol dependence	6C40.2	Approved	[50]
Midazolam	DMXOELT	Agitation	6A70.3	Approved	[51]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[33]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-2 (GABRA2)	TTBMV1G	GBRA2_HUMAN	Modulator (allosteric modulator)	[2]
GABA(A) receptor alpha-3 (GABRA3)	TT37EDJ	GBRA3_HUMAN	Modulator (allosteric modulator)	[3]
GABA(A) receptor alpha-5 (GABRA5)	TTNZPQ1	GBRA5_HUMAN	Modulator (allosteric modulator)	[4]
GABA(A) receptor gamma-3 (GABRG3)	TTEX6LM	GBRG3_HUMAN	Modulator (allosteric modulator)	[5]
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Antagonist	[6]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6)	OTX4UC3O	GBRA6_HUMAN	Protein Interaction/Cellular Processes	[7]
Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3)	OT80C3D4	GBRB3_HUMAN	Protein Interaction/Cellular Processes	[7]
Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2)	OTGNDWUO	GBRG2_HUMAN	Protein Interaction/Cellular Processes	[7]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4192).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
• [7] Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors. Mol Pharmacol. 1996 Feb;49(2):253-9.
• [8] New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [11] Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
• [12] The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
• [13] Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
• [14] Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [18] WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
• [19] 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
• [20] Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
• [21] GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202.
• [22] AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33.
• [23] Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8.
• [24] Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
• [25] Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9.
• [26] Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40.
• [27] New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9.
• [28] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [29] p-(4-Azipentyl)propofol: a potent photoreactive general anesthetic derivative of propofol. J Med Chem. 2011 Dec 8;54(23):8124-35. doi: 10.1021/jm200943f. Epub 2011 Nov 10.
• [30] Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
• [31] Heterogeneity of GABA(A) receptor-mediated responses in the human IMR-32 neuroblastoma cell line. J Neurosci Res. 2000 May 15;60(4):504-10. doi: 10.1002/(SICI)1097-4547(20000515)60:4<504::AID-JNR9>3.0.CO;2-Y.
• [32] Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J. 2005;5(2):89-95. doi: 10.1038/sj.tpj.6500292.
• [33] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [34] [3H]Ethynylbicycloorthobenzoate ([3H]EBOB) binding in recombinant GABAA receptors. Neurotoxicology. 2003 Dec;24(6):817-24. doi: 10.1016/S0161-813X(03)00051-2.
• [35] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [36] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [37] Gene expression profiling of human primary astrocytes exposed to manganese chloride indicates selective effects on several functions of the cells. Neurotoxicology. 2007 May;28(3):478-89.
• [38] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [39] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [40] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [41] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [42] GABA receptor subunit composition relative to insecticide potency and selectivity. Toxicol Lett. 2001 Jul 6;122(3):215-22. doi: 10.1016/s0378-4274(01)00366-6.
• [43] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [44] Retinoic acid, GABA-ergic, and TGF-beta signaling systems are involved in human cleft palate fibroblast phenotype. Mol Med. 2006 Sep-Oct;12(9-10):237-45. doi: 10.2119/2006C00026.Baroni.
• [45] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [46] Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons. Brain Res Mol Brain Res. 2005 Aug 18;138(2):105-15. doi: 10.1016/j.molbrainres.2004.10.047.
• [47] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [48] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [49] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [50] Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.
• [51] GABA alpha6 receptors mediate midazolam-induced anxiolysis. J Clin Anesth. 2002 May;14(3):206-9. doi: 10.1016/s0952-8180(02)00343-4.